Xilio Therapeutics, Inc. Number of Reportable Segments
Xilio Therapeutics, Inc. (XLO) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-12
- Xilio Therapeutics, Inc. number of reportable segments for the quarter ending 2025-03-31 was 1.00 segment.
- Xilio Therapeutics, Inc. number of reportable segments for fiscal 2024 was 1.00 segment.
segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 12 month |
|---|---|---|---|
| 2025-06-30 | 1.00 segment 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | 1.00 segment 10-Q · filed 2025-05-08 | ||
| 2024-12-31 | 1.00 segment 10-K · filed 2025-03-11 |
Segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-03-23 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-13 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2026-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |